Literature DB >> 12204528

Antiangiogenics meet nanotechnology.

Erkki Ruoslahti1.   

Abstract

A mutant Raf-1 gene loaded onto nanoparticles, delivered to tumor vasculature with an integrin binding compound, provides effective antiangiogenic gene therapy in mice.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12204528     DOI： 10.1016/s1535-6108(02)00100-9

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  7 in total

1.  Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents.

Authors:  Gang Zheng; Juan Chen; Hui Li; Jerry D Glickson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-23       Impact factor: 11.205

2.  Pharmacoproteomic analysis of a novel cell-permeable peptide inhibitor of tumor-induced angiogenesis.

Authors:  Ji-Young Bang; Eung-Yoon Kim; Dong-Ku Kang; Soo-Ik Chang; Moon-Hi Han; Kwang-Hyun Baek; In-Cheol Kang
Journal:  Mol Cell Proteomics       Date:  2011-05-10       Impact factor: 5.911

3.  Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents.

Authors:  Ian R Corbin; Hui Li; Juan Chen; Sissel Lund-Katz; Rong Zhou; Jerry D Glickson; Gang Zheng
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

Review 4.  Targeting vasculature in urologic tumors: mechanistic and therapeutic significance.

Authors:  Shinichi Sakamoto; A Jacqueline Ryan; Natasha Kyprianou
Journal:  J Cell Biochem       Date:  2008-02-15       Impact factor: 4.429

5.  Targeted Delivery of Neutralizing Anti-C5 Antibody to Renal Endothelium Prevents Complement-Dependent Tissue Damage.

Authors:  Paolo Durigutto; Daniele Sblattero; Stefania Biffi; Luca De Maso; Chiara Garrovo; Gabriele Baj; Federico Colombo; Fabio Fischetti; Antonio F Di Naro; Francesco Tedesco; Paolo Macor
Journal:  Front Immunol       Date:  2017-09-06       Impact factor: 7.561

Review 6.  Signaling through Raf-1 in the neovasculature and target validation by nanoparticles.

Authors:  Kishore K Wary
Journal:  Mol Cancer       Date:  2003-07-30       Impact factor: 27.401

Review 7.  Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment.

Authors:  Anita Bakrania; Gang Zheng; Mamatha Bhat
Journal:  Pharmaceutics       Date:  2021-12-25       Impact factor: 6.321
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.